



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:03
Last Report Issued 12/12/2017 11:08

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3260SP
Patient ID 3260SP
Chain 17002255
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17002255
Received 12/12/2017 07:37

Sample ID 17002255-001
Matrix Serum or Plasma
Patient Name 3260SP
Patient ID 3260SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

3260SP Oxazepam, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Oxazepam	None Detected	ng/mL	20	
----------	---------------	-------	----	--

Synonym(s): Serax®

When used as a drug, the therapeutic plasma concentration: 200 - 1400 ng/mL.
Potentially toxic greater than 2000 ng/mL.

As a metabolite of Diazepam, low concentrations may be observed. In one study, following chronic daily doses of about 70 mg of Diazepam, the steady-state serum concentrations were 50 - 400 ng Oxazepam/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.